Teva bosses issue riposte to Mylan, praise takeover plan
By Toby Sterling
AMSTERDAM (Reuters) – Executives at Israeli drugmaker Teva TEVA.TA sent an open letter to takeover target Mylan MYL.O on Monday, saying they remain committed to a deal and reiterated that Teva’s $40 billion takeover proposal would benefit shareholders of both firms.
In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak Peterburg repeated that a combination would add value to both companies.
The letter said Mylan had made “made grossly incorrect statements to mislead your stockholders and other stakeholders about usâ€.
Mylan responded later on Monday, saying Teva’s statements continue to leave it and its stakeholders with “great uncertainty†regarding the Israeli drugmaker’s intentions.
In a letter addressed to Vigodman, Coury asked for “straightforward†answers to two questions. (http://1.usa.gov/1BUOEhm)
The first is whether Teva was planning a legally binding exchange offer for Mylan.
The second is whether any such offer would contain a “hell or high water provision†under which Teva would agree to whatever the U.S. Federal Trade Commission requires to clear the transaction.
The letters are the latest in a series of unusually combative communications between the two companies.
Teva began an unsolicited pursuit of Mylan NV in April but has yet to make a formal offer as it awaits antitrust approval in the United States.
Coury has since sent two open letters criticising Teva as a poor fit for Mylan, most recently on June 1.
Spurning Teva’s advances, Mylan has begun pursuing its own unsolicited $32.7 billion bid for Perrigo of Ireland.
Coury has previously said that Teva “has engaged in a pattern of making noncommittal, unclear, inaccurate and non specific statements to shareholders … regarding its intentions with respect to Mylan.â€
Teva has built a 2.2 percent stake in Mylan ahead of making a formal offer.
Mylan has its operational headquarters in Canonsburg, Pennsylvania, but is incorporated in the Netherlands.
(Additional reporting by Natalie Grover; Editing by Pravin Char, David Evans and Simon Jennings)
- Teva
- Mylan